ArticleAIDS research and human retroviruses2021
Weight and Body Mass Index Change After Switching to Integrase Inhibitors or Tenofovir Alafenamide Among Women Living with HIV.
Abstract read
In one paragraph
Article in AIDS research and human retroviruses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV.AIDS research and therapy · 2025Trial
- Association between plasma concentrations of integrase strand transfer inhibitors and body weight gain in women with HIV.AIDS (London, England) · 2026Article
- Subclinical atherosclerosis assessed by cardio-ankle vascular index and carotid intima-media thickness in people living with HIV receiving integrase inhibitor-based tenofovir regimens.BMC infectious diseases · 2026Article
- Protective association of theFrontiers in medicine · 2026Article
- Article
- Switch to Integrase Strand Transfer Inhibitors During the Menopausal Transition Is Associated With Accelerated Body Composition Change in Women With HIV.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- Cardiovascular risk factors and cognitive performance among people living with HIV: cross-sectional study in the country of Georgia.BMJ open · 2025Article
- Weight Gain in HIV Adults Receiving Antiretroviral Treatment: Current Knowledge and Future Perspectives.Life (Basel, Switzerland) · 2024Review
- Weight Gain After HIV Therapy Initiation: Pathophysiology and Implications.The Journal of clinical endocrinology and metabolism · 2024 · on this mapReview
- Frailty-Related Factors among Women Living with and without HIV Aged 40 Years and Older. The Women's Interagency HIV Study.The Journal of frailty & aging · 2024Article
- Obesity Modifies the Relationship Between Raltegravir and Dolutegravir Hair Concentrations and Body Weight Gain in Women Living with HIV.AIDS research and human retroviruses · 2023Article
- Evidence gaps on weight gain in people living with HIV: a scoping review to define a research agenda.BMC infectious diseases · 2023Article
- META-INSTI: metabolic adverse events following integrase strand transfer inhibitor administration in spontaneous adverse event reports.Drugs in context · 2023Article
- A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection.Retrovirology · 2022Review
- Metabolic Consequences of Antiretroviral Therapy.Current HIV/AIDS reports · 2022Review
- Assessment of Obesity and Cardiometabolic Status by Integrase Inhibitor Use in REPRIEVE: A Propensity-Weighted Analysis of a Multinational Primary Cardiovascular Prevention Cohort of People With Human Immunodeficiency Virus.Open forum infectious diseases · 2021 · on this mapArticle
- Sex Differences in Non-AIDS Comorbidities Among People With Human Immunodeficiency Virus.Open forum infectious diseases · 2021Review
- Excess Weight Gain With Integrase Inhibitors and Tenofovir Alafenamide: What Is the Mechanism and Does It Matter?Open forum infectious diseases · 2021Review
- Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study.BMC infectious diseases · 2021Article
- Commentary on Lahiri et al. Weight and Body Mass Index Change After Switching to Integrase Inhibitors or Tenofovir Alafenamide Among Women Living with HIV.Journal of AIDS and HIV treatment · 2021Article
Corrections and comments
- Commented on by
Authors and funding
17 authors.
Cecile D LahiriDivision of Infectious Diseases, Department of Medicine, Emory University, Atlanta, Georgia, USA.
Yanxun XuDepartment of Applied Mathematics and Statistics, Johns Hopkins University, Baltimore, Maryland, USA.
Kunbo WangDepartment of Applied Mathematics and Statistics, Johns Hopkins University, Baltimore, Maryland, USA.
Jessica A AlvarezDivision of Endocrinology, Department of Medicine, Emory University, Atlanta, Georgia, USA.
Anandi N ShethDivision of Infectious Diseases, Department of Medicine, Emory University, Atlanta, Georgia, USA.
Jane O'HalloranDepartment of Medicine, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA.
Amanda B SpenceDivision of Infectious Disease and Travel Medicine, Department of Medicine, Georgetown University, Washington, District of Columbia, USA.
Phyllis TienDepartment of Medicine, University of California, San Francisco, San Francisco, California, USA.
Deborah R GustafsonDepartment of Neurology, State University of New York Downstate Health Sciences University, New York, New York, USA.
Joel MilamInstitute for Health Promotion & Disease Prevention Research, University of Southern California, Los Angeles, California, USA.
Margaret A FischlDepartment of Medicine, Division of Infectious Disease, University of Miami Miller School of Medicine, Miami, Florida, USA.
Deborah Konkle-ParkerDepartment of Medicine, Division of Infectious Diseases, University of Mississippi Medical Center, Jackson, Mississippi, USA.
Adaora A AdimoraDivision of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Anjali SharmaDepartment of Medicine, Albert Einstein College of Medicine, New York, New York, USA.
Kathleen M WeberCORE Center, Cook County Health, Chicago, Illinois, USA.
Igho OfotokunDivision of Infectious Diseases, Department of Medicine, Emory University, Atlanta, Georgia, USA.
Leah H RubinDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Funding
Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Monica Gandhi · 1988 to 2026
$93.6MVirology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9MVirology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0MVaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0MWOMEN'S INTERAGENCY HIV STUDY ORGANIZATION, MANAGEMENT AND COMMUNICATIONSU01AI034989 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AOUIZERAT, BRADLEY E, GREENBLATT, RUTH MARTHA · 1993 to 2018
$65.6MMulticenter Aids Cohort Study- Part B (Baltimore Site)U01AI035042 · NIAID · JOHNS HOPKINS UNIVERSITY · PI BROWN, TODD T, MARGOLICK, JOSEPH B. · 1993 to 2018
$61.5MSF Bay Area MACS/WIHS Combined Cohort StudyU01HL146242 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Bradley E Aouizerat, Jennifer Cohen Price · 2019 to 2026
$36.3MClinical Research Sites for the MACS/WIHS Combined Cohort Study (MACS/WIHS-CCS) - Baltimore/Wash DC Center - Admin Supplement: Vision and dual sensory loss in HIV-infected older adultsU01HL146201 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI TODD T BROWN, Joseph B. Margolick · 2019 to 2026
$33.7MSex differences in the role of multi-omics in HIV-associated carotid artery atherosclerosisU01HL146204 · NHLBI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI David B. Hanna, Anjali Sharma · 2019 to 2026
$33.2MMACS/WIHS Combined Cohort Study Clinical Research SiteU01HL146241 · NHLBI · EMORY UNIVERSITY · PI Cecile Delille Lahiri, Anandi Nayan Sheth · 2019 to 2026
$24.2MMWCCS: Brooklyn Clinical Research SiteU01HL146202 · NHLBI · SUNY DOWNSTATE MEDICAL CENTER · PI TRACEY ELIZABETH WILSON, Jessica Eve Yager · 2019 to 2026
$23.6MUNC MACS/WIHS Combined Cohort Study Clinical Research SiteU01HL146194 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Michael Bradley Drummond, Michelle Floris-Moore · 2019 to 2026
$23.2MNHLBI NIH HHS U01 HL146194NHLBI NIH HHS U01 HL146201NHLBI NIH HHS U01 HL146202NHLBI NIH HHS U01 HL146204NHLBI NIH HHS U01 HL146241NHLBI NIH HHS U01 HL146242NIAID NIH HHS K23 AI124913NIAID NIH HHS P30 AI027763NIAID NIH HHS P30 AI050409NIAID NIH HHS P30 AI050410NIAID NIH HHS P30 AI094189NIAID NIH HHS R38 AI140299NIAID NIH HHS U01 AI034989NIAID NIH HHS U01 AI035042NIA NIH HHS R03 AG066559NIA NIH HHS R21 AG059505NIA NIH HHS U54 AG062334
Abstract
Weight and body mass index (BMI) change was assessed among women after switch to integrase inhibitors (INSTIs) and/or tenofovir alafenamide (TAF). From 2006 to 2019, 1,458 women living with HIV enrolled in the Women's Interagency HIV Study and on antiretroviral therapy (ART) with ≥1 study visit before and after switching to INSTIs and/or TAF were included. Weight and BMI were compared pre- and postswitch to INSTI (by class and type) and/or TAF using multivariable linear mixed effects models; all models were also stratified by preswitch presence or absence of obesity (BMI ≥30 vs. <30 kg/m
Indexed as
HIV InfectionsHIV Integrase InhibitorsAdenineAlanineBody Mass IndexChildFemaleHumansTenofovirAdenineAlanineHIV Integrase InhibitorsTenofovirtenofovir alafenamidebody mass indexbody weightHIVintegrase inhibitorstenofovir alafenamidewomen
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.